As cuproptosis regulators with CNV amplification were significantly higher in GBM tissues (SLC31A1 and FDX1) and vice versa (ATP7B, DLST, and GCSH) than in normal brain tissues (Figure 1C, 1D), these genetic variations could be prominent factors altering the expression of cuproptosis regulators in patients with GBM. This evidence concerns the gene GCSH and glioblastoma.